Board of Directors

Dr. Pilkiewicz is our President and Chief Executive Officer. He formed Adgero Biopharmaceuticals, Inc. for the purpose of acquiring biotech and pharmaceutical technologies with high commercial content. Adgero acquired REM-001 Therapy and all the assets associated with it at the end of 2012.

Dr. Pilkiewicz was the Principal at Pilkiewicz Consulting and Development where he provided business and technical consulting services, primarily to the pharmaceutical and biotechnology industry and venture and early stage investment groups focused on those areas. Prior to this, he was the President and Chief Executive Officer of CellXplore, Inc., a biotechnology company focused on the treatment and diagnosis of breast cancer. Earlier, Dr. Pilkiewicz was the President and Chief Executive Officer of Transave, Inc., a pharmaceutical company that he founded following his invention of Transave, Inc.'s inhalation drug delivery technology for treating serious pulmonary diseases. Transave was acquired by Insmed in 2010 in a deal valued at over $120 million, and its lead product, Arykace, developed with the inhalation drug delivery technology invented by Dr. Pilkiewicz, is currently awaiting approval.

Previously, Dr. Pilkiewicz served as Vice President of Research & Development at The Liposome Company, Inc. where his team developed a number of commercial liposomal products including its lead products: Myocet® for metastatic breast cancer, and Abelcet® for serious fungal infections in immunocompromised patients like those with cancer. The Liposome Company was acquired by Elan in a deal valued at over $575 million. Dr. Pilkiewicz has served as a member of the board of directors of CellXplore, Inc., Charis Pharmaceutical, Inc., Transave, Inc., and OncoTherapeutics, Inc.. He is currently serving on the Life Sciences Advisory Board for the New Jersey Economic Development Authority.

Dr. Pilkiewicz earned a B.S. in chemistry from Saint Peter's University, an M.S. in organic chemistry from Rutgers University and has a Ph.D. in organic chemistry from Rutgers University. He was a Postdoctoral Research Fellow at Columbia University in organic chemistry.

Dr. Perez-Soler has been the Gutman Professor of Oncology and Chairman of the Department of Oncology at Montefiore Medical Center, and Professor of Medicine and Molecular Pharmacology and Chief of the Division of Medical Oncology at the Albert Einstein College of Medicine since July 2001. He is currently Deputy Director of the Albert Einstein Cancer Center. Dr. Perez-Soler is also currently a member of the Board of Scientific Advisors of the National Cancer Institute. Dr. Perez-Soler is an inventor in 17 patents and is well known in cancer research with over 200 scientific publications and several book chapters related to the fields of drug delivery and targeted therapies for solid tumors. His work in the field of anti-epidermal growth factor receptor therapies has received a myriad of citations. He has been the co-founder of two pharmaceutical companies, Argus Pharmaceuticals, Inc. and Transave, Inc. and has served as a consultant to a large number of pharmaceutical companies. He served as a director for Transave, Inc. from 2000 to 2006. Dr. Perez-Soler earned his M.D. from Universidad Autonoma in Barcelona, where he also completed a residency in internal medicine. He completed his fellowship in Medical Oncology at the University of Texas, M.D. Anderson Hospital Cancer Center and is a past Fulbright Scholar.

Mr. Hochman is Managing Partner of Orchestra Medical Ventures, LLC, an investment firm that employs a strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and superior investor returns. He is also President of Accelerated Technologies, Inc., a medical device accelerator company managed by Orchestra. Mr. Hochman is the Vice Chairman and a Director of Naked Brand Group Inc. He has over seventeen years of venture capital and investment banking experience. Mr. Hochman is the Chairman of Vital Access Corp. and serves as a director of MOTUS GI Medical Technologies Ltd., Caliber Therapeutics, BackBeat Medical (where he is also President), FreeHold Surgical, Maternity Neighborhood, and Prescient Medical, Inc., an interventional cardiovascular device company Mr. Hochman co-founded in 2004. Prior to joining Orchestra, Mr. Hochman was Chief Executive Officer of Spencer Trask Edison Partners, LLC, an investment partnership focused on early stage healthcare companies. He was also Managing Director of Spencer Trask Ventures, Inc., during which time he led financing transactions for over twenty early-stage companies. Mr. Hochman was a board advisor of Health Dialog Services Corporation, a leader in collaborative healthcare management that was acquired in 2008 by the British United Provident Association for $750 million. From 2005 to 2007, he was a co-founder and director of PROLOR Biotech, Inc., a biopharmaceutical company developing longer-lasting versions of approved therapeutic proteins, which was purchased by Opko Health (NYSE: OPK) in 2013 for over $600 million. Mr. Hochman also serves as a board member of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, life-threating inflammatory-fibrotic diseases with clear unmet medical needs, and two non-profit organizations: the Citizens Committee for New York City and the Mollie Parnis Livingston Foundation. He has a B.A. degree with honors from the University of Michigan.

Mr. McInerney is Principal at Two River Group, a merchant bank involved in founding, financing or managing companies that are focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease and neurological disorders, and a Partner of Riverbank Capital Securities, Inc., a FINRA/SIPC member broker dealer that provides capital raising and advisory services to companies primarily in the Life Science industry, including Two River portfolio companies. From 1992 to March 2007, Mr. McInerney was a Managing Director of Paramount BioCapital, Inc. where he oversaw the overall distribution of Paramount's private equity product. Prior to 1992, Mr. McInerney was a research analyst focusing on the biotechnology industry at Ladenburg, Thalmann & Co., Inc. Prior to that, Mr. McInerney held equity sales positions at Bear Stearns & Co. and Shearson Lehman Brothers, Inc. and worked in sales and marketing for Bristol-Myers Squibb Co. (NYSE:BMY). Mr. McInerney currently serves on the boards of Emisphere Technologies, Inc. (OTCBB:EMIS), a specialty pharmaceutical company partnered with global pharmaceutical companies for the development of new orally delivered therapeutics, and Edgemont Pharmaceuticals, LLC, a specialty pharmaceutical company focused on developing, acquiring, and commercializing improved versions of widely-prescribed products that provide meaningful clinical benefits over the current standard of care in treating psychiatric disorders. From 2008 to 2015, Mr. McInerney served as Chairman of the Board of Insite Vision, Inc. and from 2005 to 2015, he served as a director of Ziopharm Oncology Inc. (NASDAQ: ZIOP). Mr. McInerney received his B.S. in pharmacy from St. John's University. He also completed a post-graduate residency at the New York University Medical Center in drug information systems.

Mr. Murphy has over 20 years of experience in the biotechnology field. Notably, he was one of the Founders of Organovo, former CEO and Chairman Emeritus. He currently serves as the CEO of Viscient Biosciences, a company focused on the discovery and development of new drug compounds leveraging 3D bioprinting insights. Viscient expects to leverage Organovo's bioprinted liver & its other technologies thru commercial contracts just like its other pharma customers. Previously, Mr. Murphy served in Product Strategy and Director of Process Development roles at Amgen and for four of his ten years there, he served as the Global Operations Leader for the largest development program in Amgen's history, the Phase 3 osteoporosis/bone cancer drug denosumab. While at Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot.

Mr. Murphy received his B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.